(Reuters) - Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that target so-called superbugs.






source Reuters: Business News http://ift.tt/1ASReFf